Kailera Therapeutics announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions. Kailera launches with a $400 million Series A financing co-led by Atlas Venture, Bain Capital Life Sciences, and RTW Investments, with participation from Lyra Capital.

Kailera Therapeutics宣布成立一家临床阶段生物制药公司，专注于推进下一代治疗肥胖和相关疾病的广泛渠道。Kailera以Atlas Venture、Bain Capital Life Sciences和RTW Investments共同领导的4亿美元a系列融资启动，Lyra Capital参与了该项目。

The Company is developing several clinical-stage injectable and oral therapies that have demonstrated potential as best-in-class treatments for chronic weight management..

该公司正在开发几种临床阶段的注射和口服疗法，这些疗法已被证明是治疗慢性体重管理的最佳疗法。。